Research & Clinical Trials

At CEL-SCI, we are dedicated to changing the way cancer and other diseases are treated. 

Our research and development programs focus on exploiting the power of immunotherapy to develop new therapies that address the unmet medical needs of patients with cancer and infectious diseases. To that end, CEL-SCI is currently preparing to initiate a Global Phase III clinical trial of Multikine® in patients with Advanced Primary Squamous Cell Carcinoma of the Oral Cavity, a debilitating life-threatening disease, for which the overall five year survival rate has not materially improved over several decades.

For more information on Multikine®’s Phase III clinical trial design, please read Multikine® Phase III Clinical Trial Design.